Risk factor
Meaningful price volatility
Profitability factor
Greatly overvalued vs peers
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Steven Cohen | Point72 Asset Management, L.P. | 0.0% | +0.00% |
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | -0.00% |
About
Transcat, Inc. is a provider of accredited calibration and laboratory instrument services, and a value-added distributor of professional grade test, measurement, and control instrumentation. The company operates through two segments, Service and Distribution, and focuses on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceutical, biotechnology, and medical device businesses.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,
Target Price
The average target price of TRNS is 106 and suggests 22.5% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre